AstraZeneca

Preoperative treatment with anastrozole reduces need for extensive surgery

Published in Medical Device Business Week, April 7th, 2004

New data presented at EBCC 2004 indicate that preoperative (neoadjuvant) treatment with anastrozole (Arimidex; AstraZeneca) results in clinically beneficial reductions in tumor volume, extending the range of surgical options and allowing some patients to undergo less extensive surgery.

Anastrozole, one of several selective aromatase inhibitors under study, has already been shown, through the 9,366 patient ATAC ('Arimidex', Tamoxifen, Alone or in Combination) trial, to provide significant efficacy benefits compared with tamoxifen, in addition to a more favorable overall tolerability profile in the adjuvant treatment of postmenopausal women with early breast cancer...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Device Business Week

Source: Medical Device Business Week (2004-04-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry